In particular, in HER2-positive DCIS, the mechanism underlying this crosstalk might be of paramount significance for the estimation of the anticipated biological behaviour of the tumour and, hence, evaluation of the risk for disease progression/recurrence. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.